2024 Symposium to Feature New Research on ctDNA, Immunotherapy, Other Novel Treatment Options for GI Cancers

For immediate release
December 19, 2023


Rachel Cagan Faccu

ALEXANDRIA, Va. – Six studies exploring new approaches for the treatment of gastrointestinal cancers will be highlighted in the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium’s official Press Program. The research includes circulating tumor DNA (ctDNA) in colorectal cancer and new treatment options for pancreatic, liver, and esophageal cancers. Studies featured in the Press Program are among the more than 750 abstracts that will be presented at the Symposium.

The 2024 ASCO Gastrointestinal Cancers Symposium, taking place January 18-20 in San Francisco, California and online, will bring together the global GI cancer community to discuss the latest high-impact science and solution-focused strategies in the field.

The majority of abstracts will be publicly released on ASCO.org/gi-abstracts on Tuesday, January 16, 2024, at 5:00 PM (ET); late-breaking abstracts (LBAs) will publicly released at 10:00 AM (ET) on the day of presentation at the meeting and the embargoes will lift at those times. Press releases on the following abstracts will be made available to reporters covering the Meeting:

  • Outcomes from the phase III EMERALD-1 trial evaluating transarterial chemoembolization combined with durvalumab with or without bevacizumab in patients with unresectable liver cancer. (Abstract LBA432)
  • Results from the primary analysis of the phase III NETTER-2 trial examining [177Lu]Lu-DOTA-TATE in patients newly diagnosed with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors. (Abstract LBA588)
  • First results of the phase III CheckMate 8HW study evaluating nivolumab plus ipilimumab compared to chemotherapy for the treatment of microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. (Abstract LBA768)
  • Findings from an interim analysis of the phase II COBRA trial evaluating ctDNA as a predictive biomarker for adjuvant chemotherapy in patients with stage II colon cancer. (Abstract 5)
  • An updated analysis from the GALAXY trial examining ctDNA dynamics in patients with colorectal cancer. (Abstract 6)
  • Results of a phase III study evaluating tiragolumab plus atezolizumab and chemotherapy as first-line treatment in patients with esophageal cancer. (Abstract 245)


Apply for/renew ASCO media credentials: Reporters with valid ASCO media credentials will be able to access embargoed press materials and view online presentations from the 2024 Gastrointestinal Cancers Symposium. Please visit ASCO’s Media Headquarters (HQ) at mediahq.asco.org to request credentials or to ensure your credentials are up to date.

Attend the Symposium in person: Credentialed media who would like to attend the meeting in-person can register and/or reserve a hotel room through ASCO’s Media HQ. To register:

  • Sign in to your ASCO Media HQ account at mediahq.asco.org
  • Click on the “In-Person Registration and Hotel Reservations” tile

About ASCO: 

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to the principle that knowledge conquers cancer. Together with the Association for Clinical Oncology, ASCO represents nearly 50,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of high quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Conquer Cancer, the ASCO Foundation, supports ASCO by funding groundbreaking research and education across cancer’s full continuum. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on FacebookTwitterLinkedIn, Instagram, and YouTube.